Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case

Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD (known as 'Merck & Co' in the US) and Glenmark.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives

29 August 2023 Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos.

Americas

Buyers of Zetia seek class recertification after 4th circ ruling

28 September 2021 Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.

Americas

MSD and Glenmark appeal pay-for-delay Zetia dispute

7 January 2021 Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.